ClinicalTrials.gg
CompletedNCT02055820Updated Jun 11, 2020Results posted

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

A Phase 1/2 interventional study of Venetoclax and Cyclophosphamide in Lymphoma, Non-Hodgkin, sponsored by Hoffmann-La Roche. Completed at 52 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.

Enrollment
2nd of 23
267 · median 25
Started
2013
with 2 others
Phase 1/2
5 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
1 of 23
Hoffmann-La Roche

Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 5 in phase 1/2, and was the 7th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in participants with Non-Hodgkin's Lymphoma (NHL). The study consisted of 2 stages: a dose-finding Phase Ib stage and a Phase II expansion stage. In the Phase I portion of the study, participants were randomized to one of 2 treatment arms venetoclax in combination with R-CHOP (Arm A) and venetoclax in combination with G-CHOP (Arm B) and explored the doses of venetoclax in combination with R-CHOP and G-CHOP. The maximum tolerated dose (MTD) of venetoclax in combination with R-CHOP and G-CHOP was determined during the dose-finding stage. For the Phase II portion of the study, the venetoclax dose for venetoclax + R-CHOP was on a non-continuous dosing schedule as determined by the Phase Ib portion of the study based on safety and tolerability observed in participants treated in the dose escalation portion of the study. On 17 July 2016, Roche/Genentech as the sponsor of Study BO21005 (Goya study), a Phase III study that evaluated G CHOP versus R-CHOP in 1L DLBCL, informed through a press release that the primary endpoint of investigator-assessed PFS was not met. Given these results, Arm B (venetoclax + G-CHOP) was not expanded in Phase II in patients who are first-line with DLBCL.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria:

  • At least one bi-dimensionally measurable lymphoma lesion on CT scan defined as > 1.5 cm in its longest dimension, which is also FDG avid by screening PET scan.
  • Confirmed availability of archival or freshly biopsied tumor tissue prior to study enrollment
  • (ECOG) performance status of 0, 1 or 2
  • Adequate hematologic function
  • For female participants of , agreement to use highly effective forms of

Dose-Escalation Portion of the Study:

  • Participants must have confirmed B-cell NHL, except MCL or SLL
  • Participants must have never received previous R-CHOP treatment
  • Any participants that are enrolled during the dose escalation should have received only a single previous treatment regimen

Expansion Portion of the Study:

  • Participants must have previously untreated CD20-positive DLBCL and IPI score must be 2-5

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to receive any of the individual components of CHOP, rituximab or obinutuzumab
  • Prior anthracycline therapy
  • Participants with ongoing use >30 mg per day of prednisone or equivalent
  • CNS lymphoma or primary mediastinal DLBCL
  • Vaccination with within 28 days prior to randomization
  • Chemotherapy or other therapy within 28 days prior to the start of Cycle 1
  • History of other that could affect compliance with the protocol or interpretation of results
  • Evidence of significant, uncontrolled concomitant disease
  • Significant cardiovascular disease or significant pulmonary disease
  • less than (\<) 50% as defined by multiple-gated acquisition (MUGA)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1
  • Received the following agents within 7 days prior to the first dose of venetoclax: steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers; grapefruit/grapefruit products, seville oranges or star fruit within 3 days prior to the first dose of venetoclax
  • history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Recent major surgery
  • Women who are pregnant or lactating

Dose-Escalation Portion of the Study:

  • Participants with confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma (SLL)

Expansion Portion of the Study:

  • Participants with transformed lymphoma (participants with discordant bone marrow involvement (i.e., low grade histology in bone marrow) may be considered after discussion with the Medical Monitor)
  • Prior therapy for NHL
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Venetoclax + G-CHOP Arm

    Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.

    Drug: Venetoclax · Drug: Cyclophosphamide · Drug: Obinutuzumab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Experimental
    Venetoclax + R-CHOP Arm

    Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.

    Drug: Venetoclax · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

Interventions

  • Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.

    Also known as: GDC-0199, ABT-199

  • Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.

  • Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).

  • Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.

    Also known as: MabThera/Rituxan

  • Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.

  • Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.

  • Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.

06

What researchers measure

Primary outcomes

  1. Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)

    DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.

    Time frame: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)

  2. Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)

    CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy

    Time frame: Baseline up to end of treatment (up to approximately 6 months)

  3. Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC

    CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.

    Time frame: Baseline up to end of treatment (up to approximately 6 months)

Secondary outcomes

  1. Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)

    AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)

    Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)

  2. Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)

    Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

    Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

  3. Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)

    Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter

    Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

  4. Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval

    Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

    Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)

  5. Prednisone Plasma PK: AUC

    AUC was determined based on measurement of Predisone concentrations in plasma over time.

    Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

  6. Prednisone Plasma PK: Tmax

    Tmax was determined based on measurement of Predisone concentrations in plasma over time.

    Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

  7. Prednisone Plasma PK: Cmax

    Cmax was determined based on measurement of Predisone concentrations in plasma over time.

    Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)

  8. Rituximab PK: Cmax

    Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.

    Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

  9. Rituximab PK: Cmin Within the Dosing Interval

    Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2.

    Time frame: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)

  10. Obinutuzumab PK: Cmax

    Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.

    Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

  11. Cyclophosphamide PK: Cmax

    Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1.

    Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

  12. Doxorubicin PK: Cmax

    Cmax was determined using the post-dose Doxorubicin plasma concentrations.

    Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

  13. Vincristine PK: Cmax

    Cmax was determined using the post-dose Vincristine plasma concentrations.

    Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)

  14. Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC

    Objective Response defined as PR (partial response) or CR (complete response) at end of treatment. CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR

    Time frame: Baseline to end of treatment (up to approximately 6 months)

  15. Percentage of Participants Who Are Alive and Without Disease Progression at Month 12

    Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: \>/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions.

    Time frame: Month 12

  16. Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification

    CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to \</= 1.5 cm in longest transverse diameter of a lesion (LDi), no extra-lymphatic sites of disease, absence of non-measured lesions, organ enlargement must have regressed to normal, no new lesions, and if the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.

    Time frame: Baseline up to end of treatment (approx. 6 months)

  17. Safety: Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to approximately 36 months

  18. Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy

    Maintenance of relative dose intensity was defined as a dose intensity of \>/= 90%.

    Time frame: Baseline up to Cycle 6 (cycle length = 21 days)

  19. Relative Dose Intensity of Venetoclax

    Dose intensity was categorized as \< 80%, 80% to \< 85%, 85% to \< 90%, or \>/= 90%.

    Time frame: Baseline up to Cycle 6 (cycle length = 21 days)

07

Results

Posted Dec 20, 2018

Participant flow

At start the trial had a randomised-controlled component, until July 2016 once the arm B (Gazyva) got closed following the publication of results of another trial. Since July 2016, the trial was single-arm, not randomised anymore, and kept including patients in only 1 arm (Arm A, rituximab).

Phase I: Dose-Finding
Participant flow — Phase I: Dose-Finding
MilestoneVenetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP B
Started7386077666
Completed6373055666
Not completed1013022000
Withdrew: Death1012011000
Withdrew: Withdrawal by subject0000010000
Withdrew: Lost to follow-up0001001000
Phase II: Expansion
Participant flow — Phase II: Expansion
MilestoneVenetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP B
Started000020800000
Completed000015900000
Not completed00004900000
Withdrew: Death00003300000
Withdrew: Lost to follow-up0000400000
Withdrew: Withdrawal by subject00001200000

Outcome measures

PrimarySafety: Number of Participants With Dose-Limiting Toxicities (DLTs)

DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.

Time frame:
Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
Reported as:
Number · Participants
Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg + G-CHOP B
Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)101021100
PrimaryPercentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)

CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy

Time frame:
Baseline up to end of treatment (up to approximately 6 months)
Reported as:
Number · Percentage of participants
Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)
Percentage of participantsVenetoclax + R-CHOP 800 mg Phase II
Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)68.2 (61.50 to 74.47)
PrimaryPercentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC

CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.

Time frame:
Baseline up to end of treatment (up to approximately 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC
Percentage of participantsVenetoclax + R-CHOP 800 mg Phase II
Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC66.7 (55.32 to 76.76)
SecondaryVenetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)

AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)

Time frame:
Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)
Reported as:
Mean · hr*mcg/mL
Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)
hr*mcg/mLVenetoclax 800mg + R-CHOPVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax + R-CHOP 800 mgVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax + G-CHOP 800mg
Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC).66 ± NA2.51 ± .973.87 ± 2.413.70 ± 1.594.51 ± 2.322.55 ± 1.134.33 ± 1.315.13 ± 2.416.20 ± 1.71
SecondaryVenetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)

Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

Time frame:
Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Reported as:
Mean · Hour
Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)
HourVenetoclax + R-CHOP 100 mgVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax + G-CHOP 800 mg
Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)4.0 ± NA4.59 ± 1.086.50 ± 1.915.52 ± 2.075.53 ± 1.555.72 ± 1.426.56 ± 1.515.30 ± 2.385.79 ± 1.47
SecondaryVenetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)

Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter

Time frame:
Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Reported as:
Mean · Ug/ML
Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)
Ug/MLVenetoclax + R-CHOP 100 mgVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax + G-CHOP 800 mg
Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax).09 ± NA.58 ± .32.92 ± .64.85 ± .331.15 ± .48.52 ± .211.26 ± .301.00 ± .581.54 ± .37
SecondaryVenetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval

Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.

Time frame:
Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval
mcg/mLVenetoclax + R-CHOP 100 mgVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax + G-CHOP 800 mg
Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval0.0714 ± 0.000.522 ± 0.4410.253 ± 0.2470.387 ± 0.1410.640 ± 0.4510.134 ± 0.1070.395 ± 0.3810.612 ± 0.5350.628 ± 0.395
SecondaryPrednisone Plasma PK: AUC

AUC was determined based on measurement of Predisone concentrations in plasma over time.

Time frame:
Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Reported as:
Mean · hr*mcg/mL
Prednisone Plasma PK: AUC
hr*mcg/mLVenetoclax PK Popluation
Cycle 1, Day 1195 ± 72.8
Cycle 2, Day 1184 ± 81.2
SecondaryPrednisone Plasma PK: Tmax

Tmax was determined based on measurement of Predisone concentrations in plasma over time.

Time frame:
Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Reported as:
Mean · Hour
Prednisone Plasma PK: Tmax
HourVenetoclax PK Popluation
Cycle 1, Day 12.19 ± 1.61
Cycle 2, Day 13.80 ± 2.52
SecondaryPrednisone Plasma PK: Cmax

Cmax was determined based on measurement of Predisone concentrations in plasma over time.

Time frame:
Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Reported as:
Mean · Ng/ML
Prednisone Plasma PK: Cmax
Ng/MLVenetoclax PK Popluation
Cycle 1, Day 149.9 ± 28.7
Cycle 2, Day 143.2 ± 17.6
SecondaryRituximab PK: Cmax

Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.

Time frame:
End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Rituximab PK: Cmax
mcg/mLVenetoclax 800 mg
Rituximab PK: Cmax173 ± 39.4
SecondaryRituximab PK: Cmin Within the Dosing Interval

Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2.

Time frame:
Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Rituximab PK: Cmin Within the Dosing Interval
mcg/mLVenetoclax 800 mg
Rituximab PK: Cmin Within the Dosing Interval26.1 ± 13
SecondaryObinutuzumab PK: Cmax

Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.

Time frame:
End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Obinutuzumab PK: Cmax
mcg/mLVenetoclax 800 mg
Obinutuzumab PK: Cmax326 ± 76
SecondaryCyclophosphamide PK: Cmax

Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1.

Time frame:
End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Cyclophosphamide PK: Cmax
mcg/mLVenetoclax PK Popluation
Cyclophosphamide PK: Cmax32.1 ± 7.51
SecondaryDoxorubicin PK: Cmax

Cmax was determined using the post-dose Doxorubicin plasma concentrations.

Time frame:
End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Doxorubicin PK: Cmax
mcg/mLVenetoclax PK Popluation
Doxorubicin PK: Cmax1260 ± 911
SecondaryVincristine PK: Cmax

Cmax was determined using the post-dose Vincristine plasma concentrations.

Time frame:
End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Reported as:
Mean · mcg/mL
Vincristine PK: Cmax
mcg/mLVenetoclax PK Popluation
Vincristine PK: Cmax54.0 ± 44.6
SecondaryPercentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC

Objective Response defined as PR (partial response) or CR (complete response) at end of treatment. CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR

Time frame:
Baseline to end of treatment (up to approximately 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC
Percentage of ParticipantsVenetoclax + R-CHOP 800 mg Phase II
Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC81.5 (75.61 to 86.51)
SecondaryPercentage of Participants Who Are Alive and Without Disease Progression at Month 12

Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: \>/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions.

Time frame:
Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Are Alive and Without Disease Progression at Month 12
Percentage of ParticipantsVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax + R-CHOP 800 mg Phase IIVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg + G-CHOP B
Percentage of Participants Who Are Alive and Without Disease Progression at Month 1285.71 (59.79 to 100.00)100.00 (100.00 to 100.00)87.50 (64.58 to 100.00)66.67 (28.95 to 100.00)88.99 (82.65 to 92.10)100.00 (100.00 to 100.00)75.00 (32.57 to 100.00)100.00 (100.00 to 100.00)100.00 (100.00 to 100.00)100.00 (100.00 to 100.00)
SecondaryPercentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification

CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to \</= 1.5 cm in longest transverse diameter of a lesion (LDi), no extra-lymphatic sites of disease, absence of non-measured lesions, organ enlargement must have regressed to normal, no new lesions, and if the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.

Time frame:
Baseline up to end of treatment (approx. 6 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification
Percentage of ParticipantsVenetoclax + R-CHOP 800 mg Phase II
Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification37.4 (30.89 to 44.35)
SecondarySafety: Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to approximately 36 months
Reported as:
Number · Percentage of Participants
Safety: Percentage of Participants With Adverse Events
Percentage of ParticipantsVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax + R-CHOP 800 mg Phase IIVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg + G-CHOP B
Safety: Percentage of Participants With Adverse Events100.00100.00100.00100.0099.0100.00100.00100.00100.00100.00
SecondarySafety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy

Maintenance of relative dose intensity was defined as a dose intensity of \>/= 90%.

Time frame:
Baseline up to Cycle 6 (cycle length = 21 days)
Reported as:
Number · Percentage of participants
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Percentage of participantsVenetoclax + R-CHOP ArmVenetoclax 600mg + G-CHOP
Cyclophosphamide89.577.4
Doxorubicin88.677.4
Vincristine86.678.1
Prednisone87.481.3
SecondaryRelative Dose Intensity of Venetoclax

Dose intensity was categorized as \< 80%, 80% to \< 85%, 85% to \< 90%, or \>/= 90%.

Time frame:
Baseline up to Cycle 6 (cycle length = 21 days)
Reported as:
Number · Percentage of Partcipants
Relative Dose Intensity of Venetoclax
Percentage of PartcipantsVenetoclax 200 mg + R-CHOPVenetoclax 400 mg + R-CHOPVenetoclax 600 mg + R-CHOPVenetoclax 800mg + R-CHOPVenetoclax + R-CHOP 800 mg Phase IIVenetoclax 200mg + G-CHOPVenetoclax 400mg + G-CHOPVenetoclax 600mg + G-CHOPVenetoclax + G-CHOP 800 mgVenetoclax + G-CHOP 800mg B
<80%71.40.0012.50.0026.0100.0014.350.083.3100.0
80-<85%0.000.0012.50.003.40.0014.316.70.000.00
85-<90%0.000.0012.50.002.90.000.000.0016.70.00
>=90%28.6100.0062.5100.0067.60.0071.433.30.000.00

Adverse events

Collected over Baseline up to approximately 67 months. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax 200 mg +R-CHOP1/7 (14.3%)5/7 (71.4%)7/7 (100%)
Venetoclax 400 mg +R-CHOP0/3 (0%)2/3 (66.7%)3/3 (100%)
Venetoclax 600 mg +R-CHOP1/8 (12.5%)4/8 (50%)8/8 (100%)
Venetoclax 800 mg +R-CHOP4/6 (66.7%)3/6 (50%)6/6 (100%)
Venetoclax 800 mg +R-CHOP Phase II33/208 (15.9%)116/208 (55.8%)204/208 (98.1%)
Venetoclax 200 mg +G-CHOP1/7 (14.3%)5/7 (71.4%)7/7 (100%)
Venetoclax 400 mg +G-CHOP1/7 (14.3%)4/7 (57.1%)7/7 (100%)
Venetoclax 600 mg +G-CHOP0/6 (0%)3/6 (50%)6/6 (100%)
Venetoclax 800 mg + G-CHOP A0/6 (0%)5/6 (83.3%)6/6 (100%)
Venetoclax 800 mg +G-CHOP B0/6 (0%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventVenetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP B
FEBRILE NEUTROPENIABlood and lymphatic system disorders3/70/31/82/657/2081/72/70/60/61/6
ANAEMIABlood and lymphatic system disorders0/71/30/80/64/2080/70/70/60/60/6
THROMBOCYTOPENIABlood and lymphatic system disorders0/70/30/80/62/2080/70/70/62/60/6
ATRIAL FIBRILLATIONCardiac disorders1/71/30/80/66/2080/70/70/60/60/6
CARDIOMYOPATHYCardiac disorders0/71/30/80/60/2080/70/70/60/60/6
VOMITINGGastrointestinal disorders0/71/30/80/65/2080/70/70/60/60/6
NEUTROPENIABlood and lymphatic system disorders0/70/30/80/619/2081/70/70/60/61/6
CARDIAC ARRESTCardiac disorders0/70/30/80/60/2080/70/70/60/61/6
TACHYCARDIACardiac disorders0/70/30/80/61/2080/70/70/60/61/6
DYSPHAGIAGastrointestinal disorders0/70/30/80/60/2080/70/71/60/60/6
Most frequent other events
Showing 10 of 204
Most frequent other events
EventVenetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP B
NEUTROPENIABlood and lymphatic system disorders4/72/36/83/6134/2082/74/75/66/62/6
CONSTIPATIONGastrointestinal disorders1/72/33/82/667/2086/73/72/62/61/6
ANAEMIABlood and lymphatic system disorders4/70/31/82/673/2081/71/71/65/64/6
NAUSEAGastrointestinal disorders3/72/31/85/6108/2083/74/73/65/64/6
DIARRHOEAGastrointestinal disorders3/72/32/83/679/2085/73/72/62/61/6
VOMITINGGastrointestinal disorders0/71/31/82/664/2085/74/70/64/61/6
FATIGUEGeneral disorders5/70/33/82/681/2085/72/72/63/61/6
PYREXIAGeneral disorders0/70/31/82/650/2080/75/72/61/62/6
THROMBOCYTOPENIABlood and lymphatic system disorders4/71/33/80/652/2082/73/72/64/62/6
INFUSION RELATED REACTIONInjury, poisoning and procedural complications1/72/31/82/644/2084/71/72/62/63/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Venetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP BTotal
Mean67.0 ± 9.261.0 ± 13.157.0 ± 9.556.3 ± 11.961.4 ± 12.852.1 ± 16.260.9 ± 6.366.7 ± 4.260.5 ± 13.766.8 ± 6.761.2 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP BTotal
Female32229425442120
Male416411452224144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Venetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP BTotal
Hispanic or Latino00004000004
Not Hispanic or Latino612315163456187
Unknown or Not Reported1263531421073
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Venetoclax 200 mg +R-CHOPVenetoclax 400 mg +R-CHOPVenetoclax 600 mg +R-CHOPVenetoclax 800 mg +R-CHOPVenetoclax 800 mg +R-CHOP Phase IIVenetoclax 200 mg +G-CHOPVenetoclax 400 mg +G-CHOPVenetoclax 600 mg +G-CHOPVenetoclax 800 mg + G-CHOP AVenetoclax 800 mg +G-CHOP BTotal
American Indian or Alaska Native00000000000
Asian00005010006
Native Hawaiian or Other Pacific Islander00003000003
Black or African American00004000004
White612215472454187
More than one race00000000000
Unknown or Not Reported1264420421264
08

Study locations

52 sites
  • St. Jude Heritage Healthcare
    Fullerton, California 92835, United States
  • UCLA Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • Central Coast Medical Oncology
    Santa Maria, California 93454, United States
  • The West Clinici
    Saint Louis, Missouri 63129, United States
  • Hackensack University Medical Center; WFAN - Imus Pediatric Center
    Hackensack, New Jersey 07601, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department
    Rochester, New York 14642, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Peter MacCallum Cancer Centre-East Melbourne
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • LKH - Universitätsklinikum der PMU Salzburg
    Salzburg, 5020, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer Agency, CSI
    Kelowna, British Columbia V1Y 5L3, Canada
  • BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Jewish General Hospital; Research Unit
    Montréal, Quebec H3T 1E2, Canada
  • CHU de Quebec - Hôpital de l' Enfant Jésus
    Quebec, G1J 1Z4, Canada
  • Fakultni nemocnice Brno
    Brno, 613 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
    Praha 2, 128 08, Czechia
  • Hopital Henri Mondor, Unite Hemopathies lymphoides
    Creteil, 94010, France
  • Centre Hospitalier Départemental Les Oudairies
    La Roche sur Yon, 85025, France
  • Clinique Victor Hugo; Pharmacie
    Le Mans, 72015, France
  • Hopital Claude Huriez - CHU Lille
    Lille, 59037, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation
    Nantes, 44093, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud
    Pierre-Benite, 69495, France
  • CHU Rennes - Hopital Pontchaillou
    Rennes cedex 09, 35033, France
  • Centre Henri Becquerel; Hematologie
    Rouen, 76038, France
  • Hôpital de Brabois Adultes
    Vandoeuvre-les-nancy, 54511, France
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Debreceni Egyetem; Belgyogyaszati Klinika Hematologiai Tanszek
    Debrecen, 4032, Hungary
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    Napoli, Campania 80131, Italy
  • Azienda Ospedaliero Universitaria San Martino
    Genova, Liguria 16132, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, Piemonte 10126, Italy
  • Azienda Ospedaliera Vincenzo Cervello
    Palermo, Sicilia 90127, Italy
  • Azienda Ospedaliero Universitaria Pisana; U.O. Farmaceutica
    Pisa, Toscana 56100, Italy
  • Amsterdam UMC Location VUMC
    Amsterdam, 1081 HV, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • UMC Utrecht
    Utrecht, 3508 GA, Netherlands
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • ICO l´Hospitalet - Hospital Duran i Reynals; Hematology
    Barcelona, 08907, Spain
  • Hospital Universitario La Paz
    Madrid, 280146, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
09

References and documents

Publications

  • Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019 May 2;133(18):1964-1976. doi: 10.1182/blood-2018-11-880526. Epub 2019 Mar 8. PubMed 30850381 ↗
  • Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C, Sinha A, Rajwanshi R, Humphrey K, Bazeos A, Salem AH, Miles D. Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Adv Ther. 2022 Jan;39(1):598-618. doi: 10.1007/s12325-021-01919-z. Epub 2021 Nov 25. PubMed 34822104 ↗
  • Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trneny M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021 Feb 4;137(5):600-609. doi: 10.1182/blood.2020006578. Erratum In: Blood. 2021 Apr 1;137(13):1844. doi: 10.1182/blood.2021011330. PubMed 33538797 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jun 2017, 43 months.

Results were first posted in Dec 2018, 1 year 5 months after primary completion.

Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 43 months is below that.

Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2014
First posted
Feb 5, 2014
StartActual
Nov 17, 2013
Primary completionActual
Jun 28, 2017
CompletionActual
Jun 28, 2019
Results first posted
Dec 20, 2018
Last update
Jun 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02055820
Lead sponsor
Hoffmann-La Roche
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
Nov 17, 2013
Primary completion
Jun 28, 2017
Completion
Jun 28, 2019
Results posted
Dec 20, 2018
Last update
Jun 11, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Cyclophosphamide · Obinutuzumab · Rituximab · Doxorubicin · Vincristine · Prednisone

Start the discussion